Downregulation of TGFBR2, mutations in which attenuated canonical TGF-β-mediated SMAD signaling, was often found in clinical tumor samples when compared with adjacent histological normal epithelial cells and infiltrating lymphocytes [74]. The gene discussed is TGFB1; the disease is neoplasm.